Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Prospective Study for Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression or Positive FISH as Second-line Treatment

Trial Profile

A Phase II, Prospective Study for Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression or Positive FISH as Second-line Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2019

At a glance

  • Drugs Icotinib (Primary)
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
  • Most Recent Events

    • 12 Mar 2016 Results published in the Journal of Thoracic Oncology
    • 12 Mar 2016 Primary endpoint (Objective response rates [ Time Frame: 2 months ]) has been met, as per the results published in the Journal of Thoracic Oncology.
    • 12 Mar 2016 Status changed from recruiting to completed, as per the results published in the Journal of Thoracic Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top